Tag: Inhaled Insulin

MannKind Markets Afrezza to People with Type 1 Diabetes

MannKind Markets Afrezza to People with Type 1 Diabetes

The maker of inhaled insulin Afrezza is betting that relaunching their product and making it a success depends less on diabetics being afraid of…

FDA Needs More Time to Review MannKind’s New Drug Application for Inhaled Insulin

MannKind Corp. announced that it was informed today by the FDA that they will not be able to complete the review of MannKind's new drug application for its ultra rapid-acting insulin therapy by the action date of January 16, 2010.The FDA explained that it has not yet completed its inspection of the insulin manufacturing facilities of N.V. Organon, a third-party supplier to MannKind....